FDA Drug Shortages

Current and Resolved Drug Shortages and Discontinuations Reported to FDA

Start Over | Back to Previous Screen

Temozolomide Capsules
Status: Discontinuation
»Therapeutic Categories: Oncology

Expand all

Merck Sharp & Dohme Corp. (New 04/23/2021)

Company Contact Information:
800-672-6372

Presentation Posting Date Related Information
TEMODAR Capsules, 100 mg; child-resistant sachets, 5 count (NDC 0085-1366-03) 04/23/2021 To be discontinued on or near October 2021
TEMODAR Capsules, 100 mg; child-resistent sachets, 14-count (NDC 0085-1366-04) 04/23/2021 To be discontinued on or near October 2021
TEMODAR Capsules, 140 mg, child-resistant sachets, 14-count (NDC 0085-1425-04) 04/23/2021 To be discontinued on or near October 2021
TEMODAR Capsules, 180 mg; child-resistent sachets, 5 count (NDC 0085-1430-03) 04/23/2021 To be discontinued on or near October 2021
TEMODAR Capsules, 250 mg; child-resistent sachets, 5 count (NDC 0085-1417-02) 04/23/2021 To be discontinued on or near April 2022

Teva Pharmaceuticals (New 05/08/2020)

Company Contact Information:
800-545-8800

Presentation Posting Date Related Information
5 mg (NDCs 0093-7599-41 and 0093-7599-57) 05/08/2020
20 mg (NDCs 0093-7600-41 and 0093-7600-57) 05/08/2020
100 mg (NDCs 0093-7601-41 and 0093-7601-57) 05/08/2020
140 mg (NDCs 0093-7638-41 and 0093-7638-57) 05/08/2020
180 mg (NDCs 0093-7639-41 and 0093-7639-57) 05/08/2020
250 mg (NDC 0093-7602-57) 05/08/2020

Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English